Drug Trial Radar · NCT07909837
A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Nanjing Chia-tai Tianqing PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of single oral doses of NTQ6179 tablets in healthy participants. A total of 56 healthy participants will be enrolled in 7 sequential dose cohorts, with an allocation ratio of NTQ6179 to placebo of 6:2 in each cohort.
Conditions
- Acromegaly
Interventions
NTQ6179Drug
NTQ6179 tablets, an oral non-peptide small-molecule somatostatin receptor subtype 2 (SSTR2) agonist, administered orally as a single dose with approximately 240 milliliters (mL) of water under fasting conditions (at least 10 hours of overnight fasting prior to dosing).
NTQ6179 placeboDrug
NTQ6179 placebo tablets administered orally as a single dose with approximately 240 milliliters (mL) of water under fasting conditions (at least 10 hours of overnight fasting prior to dosing).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs), treatment-related TEAEs (TRAEs), and serious adverse events (SAEs)Time frame: Up to the end of follow-up (Day 13 ± 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.